On July 21, 2025, Unity Biotechnology, Inc. filed an 8-K to announce that they issued a Series A Preferred Share to their President for $1.00 as part of their plan to dissolve the company following a Board decision on June 27, 2025. This move allows the holder to vote on dissolution proposals in relation to the company’s restructuring.